Figure 3 represents the cumulative risk of developing composite outcome and mortality in COVID-19 patients treated with Nirmatrelvir, whose peripheral blood CD4+ T cell and CD8+ T cell counts decreased significantly at admission. The gene discussed is CD8A; the disease is COVID-19.